key: cord-0981417-nh86xfbt
authors: Barker, Madeleine; Sathananthan, Janarthanan; Perdoncin, Emily; Devireddy, Chandan; Keegan, Patricia; Grubb, Kendra; Pop, Andrei M.; Depta, Jeremiah P.; Rai, Devesh; Abtahian, Farhad; Spence, Mark S.; Mailey, Jonathan; Muir, Douglas F.; Russo, Mark J.; Pineda-Salazar, Jennifer; Okoh, Alexis; Smith, Meghan; Dahle, Thom G.; Rana, Masud; Alfadhel, Mesfer; Meier, David; Chatfield, Andrew; Akodad, Mariama; Chuang, Anthony; Samuel, Rohit; Nestelberger, Thomas; McAlister, Cameron; Lauck, Sandra; Webb, John G.; Wood, David A.
title: Same-Day Discharge Post–Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic: The Multicenter PROTECT TAVR Study
date: 2022-03-28
journal: JACC Cardiovasc Interv
DOI: 10.1016/j.jcin.2021.12.046
sha: fcb5609405fa6968b540b52e1831c6c851e719be
doc_id: 981417
cord_uid: nh86xfbt

OBJECTIVES: The aim of this study was to determine the safety and efficacy of same-day discharge (SDD) after transcatheter aortic valve replacement (TAVR) during the COVID-19 pandemic. BACKGROUND: The COVID-19 pandemic has placed significant stress on health care systems worldwide. SDD in highly selected TAVR patients can facilitate the provision of essential cardiovascular care while managing competing COVID-19 resource demands. METHODS: Patient selection for SDD was at the discretion of the local multidisciplinary heart team, across 7 international sites. The primary outcome was a composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new permanent pacemaker (PPM) implantation. RESULTS: From March 2020 to August 2021, 124 of 2,100 patients who underwent elective transfemoral TAVR were selected for SDD. The average age was 78.9 ± 7.8 years, the median Society of Thoracic Surgeons score was 2.4 (IQR: 1.4-4.2), and 32.3% (n = 40) had preexisting PPMs. There were no major vascular complications, strokes, or deaths during the index admission. One patient (0.8%) required PPM implantation for complete heart block and was discharged the same day. No patient required a PPM between discharge home and 30-day follow-up. The composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new PPM at 30 days occurred in 5.7% patients (n = 6 of 106). CONCLUSIONS: SDD post-TAVR is safe and feasible in selected patients at low risk for adverse clinical events postdischarge. This strategy may have a potential role in highly selected patients even when the COVID-19 pandemic abates.

T he COVID-19 pandemic has placed considerable stress on health care systems and has resulted in delays in many cardiovascular procedures, including transcatheter aortic valve replacement (TAVR). [1] [2] [3] [4] Cardiovascular societies worldwide have provided guidance to maintain essential structural interventional procedures while minimizing critical care bed use and burden on hospitals. [1] [2] [3] [4] Given the high morbidity and mortality associated with delays in treating patients with severe symptomatic aortic stenosis, continued access to structural interventional procedures is essential. 5 The safety of next-day discharge (NDD) post-TAVR using a standardized clinical care pathway has been well established through multicenter studies.

Knowledge translation programs focused on achieving safe NDD, such as the Edwards Benchmark program, have implemented this approach globally. 6, 7 This strategy consists of team-based quality improvement initiatives aimed at facilitating implementation of best practices for TAVR, from admission to discharge. In particular, clinical care pathways lead to a decreased need for critical care monitoring, rapid reconditioning, and avoidance of in-hospital complications, with excellent safety outcomes. [6] [7] [8] [9] Same-day discharge (SDD) post-TAVR in carefully selected patients may allow maintenance of TAVR volumes while preserving necessary hospital resources to address the pandemic as cases wax and wane. Small single-center case series during the COVID-19 pandemic have demonstrated that SDD post-TAVR is feasible in highly selected patients; however, the data remain limited. [10] [11] [12] [13] In this international multicenter observational study, we aimed to evaluate the safety and feasibility of SDD in highly selected patients who underwent elective transfemoral TAVR during the COVID-19 pandemic. Table 3) . The rate of all-cause Patient selection for same-day discharge. SDD ¼ same-day discharge;

TAVR ¼ transcatheter aortic valve replacement. Table 3) . Valve Implantation) studies had rates of 5.7% and 4.3% for PPM implantation post-TAVR, respectively, and rates of 5.7% and 3.7% for cardiovascular readmission at 30 days, compared with a 0.8% PPM rate and a 2.8% cardiovascular readmission rate in this cohort. 6, 7 Although these studies were larger, with more lenient inclusion criteria, the safety observed with SDD in our study is encouraging.

The centers included in this study were experienced, with a minimalist NDD approach to TAVR, Abbreviations as in Table 1 . pandemic abates. WHAT IS NEXT? Using the proposed SDD clinical pathway, this strategy may have a potential role in highly selected patients even when the COVID-19 pandemic abates.

Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: guidance from Canadian Association of Interventional Cardiology

Safe reintroduction of cardiovascular services during the COVID-19 pandemic: from the North American society leadership

Safe reintroduction of cardiovascular services during the COVID-19 pandemic: from the North American society leadership

ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic

Mortality while waiting for aortic valve replacement

The Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: the 3M TAVR study

Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial

Feasibility and safety of adopting next-day discharge as first-line option after transfemoral transcatheter aortic valve replacement

Predictors and clinical outcomes of next-day discharge after minimalist transfemoral transcatheter aortic valve replacement

Safety of same-day discharge after uncomplicated, minimalist transcatheter aortic valve replacement in the COVID-19 era. Catheter Cardiovasc Interv

endpoint definitions for aortic valve clinical research

Management of conduction disturbances associated with transcatheter aortic valve replacement: JACC scientific expert panel

Arrhythmic burden as determined by ambulatory continuous cardiac monitoring in patients with new-onset persistent left bundle branch block following transcatheter aortic valve replacement: the MARE study

Implications of transcatheter heart valve selection on early and late pacemaker rate and on length of stay

Comparison of balloon-expandable vs. selfexpandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration

KEY WORDS COVID-19 pandemic, sameday discharge, transcatheter aortic valve replacement